At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 13, 2026 at 11:47 ET
Boston Partners filed an amended Schedule 13G disclosing a 6.16% passive stake in Cytek Biosciences as of September 30, 2026, up from a prior 5.6% stake. The increase is modest and routine for a passive institutional investor.
- Boston Partners reported beneficial ownership of 8,002,638 shares of Cytek Biosciences common stock as of September 30, 2026.
- The stake represents 6.16% of shares outstanding, up from 5.6% in the prior filing.
- Boston Partners is a registered investment adviser filing under Rule 13d-1(b) as a passive investor.
- The filing certifies the securities were acquired and are held in the ordinary course of business, not to influence control.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access